Breakthrough in plant-based production of Cyxone’s T20K

Cyxone (publ), a biotech company in autoimmune diseases, is developing T20K which acts to stop or slow down the progression of Multiple Sclerosis (MS). Researchers at the well renowned Center of Excellence for Innovations in Peptide and Protein Science, Australia have demonstrated a breakthrough in plant-based production of Cyxone’s T20K.The research findings means that sustainable, large scale and cost-effective production of cyclotide-based pharmaceuticals such as T20K, are now within reach.Since cyclotides are gene-encoded plant peptides, Professor David Craik and his team at University